<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548025" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548025/" /><meta name="ncbi_pagename" content="Ethionamide - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Ethionamide - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Ethionamide" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/12/26" /><meta name="citation_pmid" content="31643357" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548025/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Ethionamide" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/12/26" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548025/" /><meta name="description" content="Ethionamide is a second line drug in the therapy of tuberculosis used only in combination with other agents and for drug-resistant tuberculosis. Ethionamide has been linked to transient, asymptomatic elevations in serum aminotransferase levels and in uncommon instances of acute liver injury, which can be severe." /><meta name="og:title" content="Ethionamide" /><meta name="og:type" content="book" /><meta name="og:description" content="Ethionamide is a second line drug in the therapy of tuberculosis used only in combination with other agents and for drug-resistant tuberculosis. Ethionamide has been linked to transient, asymptomatic elevations in serum aminotransferase levels and in uncommon instances of acute liver injury, which can be severe." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548025/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Ethionamide/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548025/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B33EC04669F8100000000050E0159.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548025_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548025_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Ethambutol/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Ethosuximide/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548025_"><span class="title" itemprop="name">Ethionamide</span></h1><p class="small">Last Update: <span itemprop="dateModified">December 26, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Ethionamide.OVERVIEW"><h2 id="_Ethionamide_OVERVIEW_">OVERVIEW</h2><div id="Ethionamide.Introduction"><h3>Introduction</h3><p>Ethionamide is a second line drug in the therapy of tuberculosis used only in combination with other agents and for drug-resistant tuberculosis. Ethionamide has been linked to transient, asymptomatic elevations in serum aminotransferase levels and in uncommon instances of acute liver injury, which can be severe.</p></div><div id="Ethionamide.Background"><h3>Background</h3><p>Ethionamide (eth" eye on' a mide) is a thio-isonicotinamide somewhat similar in structure to isoniazid. Ethionamide is a prodrug and, like isoniazid, requires activation whereupon it inhibits mycobacterial fatty acid synthesis (enoyl-ACP reductase) that is necessary for cell wall synthesis and repair. Interestingly, there is little cross resistance between isoniazid and ethionamide, probably because they are activated by different mycobacterial enzymes, and therefore can be used together. Ethionamide is currently used only as a secondary agent in the treatment of active tuberculosis, always in combination with other antituberculosis agents such as isoniazid, ethambutol, pyrazinamide and/or rifampin and usually for multidrug resistant mycobacterial infections or in situations where first line agents are contraindicated. Ethionamide also has activity against lepromatous leprosy. Ethionamide is available as 250 mg tablets in generic forms and under the brand name Trecator. The typical dose in adults is 250 mg twice daily, but can then be increased gradually to a total dose of 15 to 20 mg/kg per day to a maximum of 1 gram given either once or in two divided doses daily. Pyridoxine (vitamin B6: 50 mg daily) is usually administered with ethionamide. Common side effects include gastrointestinal upset, nausea, anorexia, diarrhea, metallic taste, stomatitis, depression, drowsiness and fatigue. Severe adverse events include mycobacterial resistance, hypersensitivity reactions and severe cutaneous reactions including Stevens Johnson syndrome, toxic epidermal necrolysis and DRESS syndrome.</p><p>The management of multidrug resistant tuberculosis is challenging and should be under the direction of physicians with expertise in tuberculosis therapy and management of its side effects. Optimal regimens of therapy for tuberculosis are complex and change frequently. Regularly updated recommendations on use of drugs for tuberculosis, including indications, contraindications, warnings, dosages and monitoring recommendations are available at the Centers for Disease Control and Prevention website:&#x000a0;<a href="https://www.cdc.gov/tb/publications/guidelines/Treatment.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.cdc.gov/tb/publications/guidelines/Treatment.htm</a>.</p></div><div id="Ethionamide.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Ethionamide therapy has been linked to elevations in serum aminotransferase levels in a proportion of patients, but these elevations are typically self-limited and asymptomatic. More importantly, ethionamide has been linked to many instances of clinical apparent acute liver injury that arise in up to 5% of patients and can be severe and even fatal. The time to onset and clinical features of hepatic injury due to ethionamide resemble those of isoniazid, the latency ranging from 2 weeks to more than 6 months after starting (most arise within 1 to 3 months), and the pattern of enzyme elevations typically being hepatocellular and resembling acute viral hepatitis. Features of hypersensitivity (rash, fever and eosinophilia) are uncommon. Like isoniazid, ethionamide therapy may be associated with development of autoantibodies (typically ANA), but titers are generally low and rarely accompanied by autoimmune conditions. Cases of severe hypersensitivity reaction including Stevens Johnson Syndrome and DRESS which can be accompanied by liver injury have been described with ethionamide.</p><p>Likelihood score: B (highly likely although rare cause of clinically apparent liver injury).</p></div><div id="Ethionamide.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Ethionamide is extensively metabolized by the liver and liver injury likely is due to a toxic or immunologically active intermediate. Rapid recurrence of injury upon rechallenge suggests a hypersensitivity reaction.</p></div><div id="Ethionamide.Outcome_and_Management"><h3>Outcome and Management</h3><p>Serum aminotransferase elevations during ethionamide therapy are generally transient and asymptomatic, but elevations accompanied by symptoms of hepatitis and those above five times ULN should lead to prompt discontinuation. Monitoring of serum aminotransferase levels is indicated in patients with underlying liver disease receiving ethionamide and in those with a high risk of developing hepatotoxicity. Some cases of ethionamide hepatotoxicity have been severe and fatal instances have been reported. Cross reactivity to hepatic injury between isoniazid and ethionamide has not been shown, and several patients with clinically apparent liver injury due to ethionamide have later tolerated isoniazid without difficulty.</p><p>[First line medications used in the therapy of tuberculosis in the US include ethambutol, isoniazid, pyrazinamide, rifabutin, rifampin, and rifapentine. Second line medications include streptomycin, capreomycin, cycloserine, ethionamide, pretomanid, fluoroquinolones such as levofloxacin and moxifloxacin, aminoglycosides such as amikacin, and para-aminosalicylic acid (PAS).]</p><p>Drug Class: <a href="/books/n/livertox/AntituberculosisAgen/">Antituberculosis Agents</a></p><p>Other Drugs in the Class: <a href="/books/n/livertox/Bedaquiline/">Bedaquiline</a>, <a href="/books/n/livertox/Capreomycin/">Capreomycin</a>, <a href="/books/n/livertox/Cycloserine/">Cycloserine</a>, <a href="/books/n/livertox/Ethambutol/">Ethambutol</a>, <a href="/books/n/livertox/Isoniazid/">Isoniazid</a>, <a href="/books/n/livertox/Pretomanid/">Pretomanid</a>, <a href="/books/n/livertox/Pyrazinamide/">Pyrazinamide</a>, <a href="/books/n/livertox/Rifabutin/">Rifabutin</a>, <a href="/books/n/livertox/Rifampin/">Rifampin</a>, <a href="/books/n/livertox/Rifapentine/">Rifapentine</a>, <a href="/books/n/livertox/Streptomycin/">Streptomycin</a></p></div></div><div id="Ethionamide.PRODUCT_INFORMATION"><h2 id="_Ethionamide_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Ethionamide &#x02013; Trecator&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antituberculosis Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=ethionamide" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Ethionamide.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Ethionamide_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Ethionamide.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548025/table/Ethionamide.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ethionamide.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Ethionamide.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Ethionamide.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Ethionamide.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Ethionamide.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Ethionamide.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ethionamide</td><td headers="hd_h_Ethionamide.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134977613" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">536-33-4</a></td><td headers="hd_h_Ethionamide.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C8-H10-N2-S</td><td headers="hd_h_Ethionamide.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134977613" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134977613" alt="image 134977613 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Ethionamide.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Ethionamide_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 16 December 2020</p><p>Abbreviations: DRESS, drug rash with eosinophilia and systemic symptoms; HIV, human immunodeficiency virus; MAC, Mycobacterium avium complex; PAS, para-aminosalicylic acid; SJS, Stevens Johnson syndrome; TEN, toxic epidermal necrolysis.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Ethionamide.REF.zimmerman.1999">Zimmerman HJ. Antituberculosis agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 611-21.<div><i>(Extensive review of hepatotoxicity of antituberculosis medications including ethambutol published in 1999; mentions that ethionamide has been reported to cause liver injury in 3-5% of patients).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.verma.2011">Verma S, Kaplowitz N. Hepatotoxicity of antituberculosis drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2011, pp. 483-504.<div><i>(Review of hepatotoxicity of antituberculosis drugs).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.gumbo.2018">Gumbo T. Chemotherapy of tuberculosis, mycobacterium avium complex disease and leprosy. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1067-86.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.clarke.1961.636">Clarke GBM, O'Hea AJ. Chronic pulmonary tuberculosis treatment with ethionamide combined with cycloserine or oxytetracycline. <span><span class="ref-journal">Br Med J. </span>1961;<span class="ref-vol">1</span>:636–8.</span> [<a href="/pmc/articles/PMC1953486/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1953486</span></a>] [<a href="/pubmed/13693888" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13693888</span></a>]<div><i>(Among 12 patients with drug resistant tuberculosis treated with ethionamide and either cycloserine or oxytetracycline, 1 developed jaundice after 14 weeks [peak bilirubin 12 mg/dL, Alk P 3 times ULN], which was attributed to ethionamide and resolved 3 months after stopping).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.slavin.1962.745">Slavin P. Ethionamide in re-treatment of eleven patients with pulmonary tuberculosis. <span><span class="ref-journal">Am Rev Respir Dis. </span>1962;<span class="ref-vol">85</span>:745–9.</span> [<a href="/pubmed/13913830" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13913830</span></a>]<div><i>(Experience in treating 11 patients with drug resistant tuberculosis using ethionamide in combination with multiple agents; 2 patients developed liver injury, but both improved with stopping pyrazinamide while continuing ethionamide).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.phillips.1962.268">Phillips S, Trevathan RD. Serum glutamic oxaloacetic transaminase elevation and possible hepatotoxicity accompanying the administration of ethionamide. <span><span class="ref-journal">Am Rev Respir Dis. </span>1962;<span class="ref-vol">86</span>:268–9.</span> [<a href="/pubmed/14486256" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14486256</span></a>]<div><i>(49 patients with tuberculosis had AST testing during ethionamide therapy; 2 developed elevations at 2 and 6 months, peak levels 83 and 215 U/L, mild symptoms but no jaundice).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.moulding.1962.252">Moulding TS Jr, Goldstein S. Hepatotoxicity due to ethionamide. <span><span class="ref-journal">Am Rev Respir Dis. </span>1962;<span class="ref-vol">86</span>:252–5.</span> [<a href="/pubmed/14476629" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14476629</span></a>]<div><i>(33 year old man developed jaundice 8 months after starting ethionamide and 6 months after blood transfusions [bilirubin 5.8 mg/dL, AST 520 U/L, Alk P 3 times ULN], improving on stopping and worsening again on restarting ethionamide; later tolerated isoniazid without recurrence; discusses 12 further cases in the literature).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.petty.1962.503">Petty TL, Mitchell RS. Successful treatment of advanced isoniazid- and streptomycin-resistant pulmonary tuberculosis with ethionamide, pyrazinamide, and isoniazid. <span><span class="ref-journal">Am Rev Respir Dis. </span>1962;<span class="ref-vol">86</span>:503–12.</span> [<a href="/pubmed/13942996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13942996</span></a>]<div><i>(Among 70 patients with isoniazid or streptomycin resistance treated with ethionamide, 12 developed AST elevations, but abnormalities were attributed to pyrazinamide; one patient died of liver failure but was also taking isoniazid and pyrazinamide and drinking heavily).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.phillips.1963.896">Phillips S, Tashman H. Ethionamide jaundice. <span><span class="ref-journal">Am Rev Respir Dis. </span>1963;<span class="ref-vol">87</span>:896–8.</span> [<a href="/pubmed/13943168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13943168</span></a>]<div><i>(59 year old man developed abnormal liver tests 5 weeks after starting ethionamide and streptomycin for active tuberculosis which worsened by 8 weeks [bilirubin 3.2 mg/dL, AST 1170 U/L, Alk P normal], resolving rapidly on stopping and not recurring subsequently with streptomycin and isoniazid therapy).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.lees.1963.158">Lees AW. Jaundice due to ethionamide. <span><span class="ref-journal">Br J Dis Chest. </span>1963;<span class="ref-vol">57</span>:158–61.</span> [<a href="/pubmed/14043687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14043687</span></a>]<div><i>(3 of 62 patients with tuberculosis treated with ethionamide developed jaundice; all 3 were women, ages 54 to 72 years with onset 1-4 months after starting ethionamide in combination with either isoniazid or streptomycin [peak bilirubin 3.0-5.8 mg/dL, Alk P 2-3 times ULN], resolving after 1-4 months; one had positive rechallenge with ethionamide; all later tolerated isoniazid without recurrence).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.elkhoury.1964.15">El-Khoury SA, Dunmore LA Jr. Ethionamide and hepatotoxicity: a clinical study. <span><span class="ref-journal">Med Ann Dist Columbia. </span>1964;<span class="ref-vol">33</span>:15–7.</span> [<a href="/pubmed/14116699" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14116699</span></a>]<div><i>(Analysis of hepatotoxicity in 40 patients with tuberculosis treated with ethionamide for 4-14 months [750 mg daily] in various combinations; 3 patients had BSP elevations, but ALT and AST were normal or minimally elevated and none developed jaundice or Alk P elevations).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.conn.1964.542">Conn HO, Binder HJ, Orr HD. Ethionamide-induced hepatitis. A review with a report of an additional case. <span><span class="ref-journal">Am Rev Respir Dis. </span>1964;<span class="ref-vol">90</span>:542–52.</span> [<a href="/pubmed/14221666" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14221666</span></a>]<div><i>(35 year old man with tuberculosis and multiple relapses, developed fatigue 6 weeks after starting ethionamide and cycloserine, improving on stopping and redeveloping symptoms 1 week after restarting [bilirubin 0.7 mg/dL, AST 500, Alk P 6 times ULN], resolving rapidly on stopping ethionamide only; biopsy showed centrolobular necrosis).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.nagasawa.1964.139">Nagasawa J, Mikami R. The side effects of ethionamide with emphasis on its hepatotoxicity. <span><span class="ref-journal">Bull Int Union Tuberc. </span>1964;<span class="ref-vol">35</span>:139–41.</span> [<a href="/pubmed/14269361" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14269361</span></a>]<div><i>(Two Japanese women with tuberculosis, ages 34 and 57 years, developed acute liver failure after 1.5 and 7 months of ethionamide therapy, whose autopsies showed massive necrosis; among 50 patients studied prospectively, 36% were said to develop abnormal liver tests, based on serial BSP, icterus index and cephalin-flocculation).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.aquinas.1964.181">Aquinas SM. Reactions to antituberculosis drugs among Chinese in Hong Kong. <span><span class="ref-journal">Tubercle. </span>1964;<span class="ref-vol">45</span>:181–7.</span> [<a href="/pubmed/14227802" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14227802</span></a>]<div><i>(Among 389 patients treated with pyrazinamide and ethionamide for tuberculosis, side effects requiring discontinuation of therapy occurred in 4 [1%], including 3 with jaundice [all attributed to pyrazinamide], one of whom died).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.de_voogd.1964.357">De Voogd A. <span><span class="ref-journal">Rev Tuberc Pneumol (Paris). </span>1964;<span class="ref-vol">28</span>:357–60.</span> [Development of a benign catarrhal jaundice in a child subjected to ethionamide treatment] French. [<a href="/pubmed/14182144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14182144</span></a>]<div><i>(5 year old girl with tuberculosis developed jaundice 3 months after starting isoniazid, ethionamide and PAS [ALT 750 U/L; interpreted as viral hepatitis], all three agents being restarted after recovery and patient tolerated final 3 months of therapy).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.schwartz.1966.685">Schwartz WS. Comparison of ethionamide with isoniazid in original treatment cases of pulmonary tuberculosis. XIV. A report of the Veterans Administration&#x02014;Armed Forces cooperative study. <span><span class="ref-journal">Am Rev Respir Dis. </span>1966;<span class="ref-vol">93</span>:685–92.</span> [<a href="/pubmed/5936929" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5936929</span></a>]<div><i>(Controlled trial of ethionamide vs isoniazid with streptomycin in 236 patients with active tuberculosis; similar efficacy but higher rate of toxicity with ethionamide [39% vs 11% requiring discontinuation], jaundice appearing in 1 [1%] and abnormal AST levels in 10 patients [~10%] on ethionamide).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.byrd.1974.560">Byrd RB, Kaplan PD, Gracey DR. Treatment of pulmonary tuberculosis. <span><span class="ref-journal">Chest. </span>1974;<span class="ref-vol">66</span>:560–7.</span> [<a href="/pubmed/4139002" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4139002</span></a>]<div><i>(Review of therapy of tuberculosis; ethionamide is discussed as potentially causing hepatitis).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.rossouw.1975.1">Rossouw JE, Saunders SJ. Hepatic complications of antituberculous therapy. <span><span class="ref-journal">Q J Med. </span>1975;<span class="ref-vol">44</span>:1–16.</span> [<a href="/pubmed/50605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 50605</span></a>]<div><i>(Summary of hepatic complications among 7492 cases of tuberculosis treated between 1960 and 1973 using various antituberculosis regimens; among 38 cases of hepatitis [0.3%] with 5 deaths from hepatic failure, 3 were associated with ethionamide therapy, specific details on these three were not given).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.pattyn.1984.1">Pattyn SR, Janssens L, Bourland J, Saylan T, Davies EM, Grillone S, Feracci C. Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy. <span><span class="ref-journal">Int J Lepr Other Mycobact Dis. </span>1984;<span class="ref-vol">52</span>:1–6.</span> [<a href="/pubmed/6368424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6368424</span></a>]<div><i>(Among 596 patients with leprosy treated with rifampin and ethionamide [and either dapsone or clofazimine], 23 [4.5%] developed hepatitis arising after 5-186 days [mean 93 days], with mortality of 26% attributed to drug combination).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.see.1986.129">See A, Hervio P, Bouvry M. <span><span class="ref-journal">Ann Gastroenterol Hepatol (Paris). </span>1986;<span class="ref-vol">22</span>:129–30.</span> [The hepatotoxicity of ethionamide remains a topical subject. Apropos of a case of acute hepatitis] French. [<a href="/pubmed/3729286" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3729286</span></a>]<div><i>(22 year old man with leprosy and HBsAg carrier state developed jaundice and pruritus 2 years after starting thalidomide, rifampin, ethionamide and clofazimine [bilirubin 6.4 mg/dL, ALT 15 times ULN, Alk P 287 U/L, prothrombin index 60%], recovering within 4-5 months of stopping ethionamide and rifampin).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.donald.1987.741">Donald PR, Schoeman JF, O'Kennedy A. Hepatic toxicity during chemotherapy for severe tuberculosis meningitis. <span><span class="ref-journal">Am J Dis Child. </span>1987;<span class="ref-vol">141</span>:741–3.</span> [<a href="/pubmed/2884866" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2884866</span></a>]<div><i>(Among 56 children with tuberculosis meningitis treated with isoniazid, rifampin, pyrazinamide and ethionamide, ALT elevations occurred in 72%, but only one child developed jaundice which was attributed to hepatitis A).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.donald.1998.704">Donald PR, Schoeman JF, Van Zyl LE, De Villiers JN, Pretorius M, Springer P. Intensive short course chemotherapy in the management of tuberculous meningitis. <span><span class="ref-journal">Int J Tuberc Lung Dis. </span>1998;<span class="ref-vol">2</span>:704–11.</span> [<a href="/pubmed/9755923" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9755923</span></a>]<div><i>(Among 95 children with tuberculous meningitis treated with a 6 month course of isoniazid, rifampin, pyrazinamide and ethionamide, 10 developed elevated bilirubin levels during 2-4 weeks of therapy, but these resolved with or without stopping therapy; one child had hepatitis A, and 14% had transient AST or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.american_thoracic_society.2003.1">American Thoracic Society. Centers for Disease Control and Prevention (CDC).  Infectious Diseases Society of America. Treatment of tuberculosis. <span><span class="ref-journal">MMWR Recomm Rep. </span>2003;<span class="ref-vol">52</span>(RR-11):1–77.</span> [<a href="/pubmed/12836625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12836625</span></a>]<div><i>(Recommendations for therapy of tuberculosis including details of drug regimens, side effects, monitoring and optimal approaches to follow up; ethionamide is a second line agent).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.di_perri.2004.593">Di Perri G, Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? <span><span class="ref-journal">J Antimicrob Chemother. </span>2004;<span class="ref-vol">54</span>:593–602.</span> [<a href="/pubmed/15282233" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15282233</span></a>]<div><i>(Multidrug resistance is defined as an organism resistant to at least isoniazid and rifampin; authors rank second line agents as: 1. levofloxacin, aminoglycosides, and capreomycin, 2. ethionamide, ofloxacin and ciprofloxacin, 3. PAS, 4. cycloserine, 5. amoxicillin/clavulanate or ampicillin/sulbactam, 6. clarithromycin, linezolid and clofazimine).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.fajardo.2006.457">Fajardo TT, Guinto RS, Cellona RV, Abalos RM, Dela Cruz EC, Gelber RH. A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. <span><span class="ref-journal">Am J Trop Med Hyg. </span>2006;<span class="ref-vol">74</span>:457–61.</span> [<a href="/pubmed/16525107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16525107</span></a>]<div><i>(Among 46 patients with leprosy treated with either ethionamide or prothionamide for 6 months, elevations in AST [35-88 U/L] occurred in 18 [39%], often resolving despite continuing medication, and only one patient developed jaundice [on prothionamide]).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, no case was attributed to ethionamide).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF27">Ethionamide. <span><span class="ref-journal">Tuberculosis (Edinb). </span>2008;<span class="ref-vol">88</span>:106–8.</span> [<a href="/pubmed/18486043" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18486043</span></a>]<div><i>(Brief review of the structure, mechanism of action, resistance, efficacy and safety of ethionamide).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.abubakar.2009.512">Abubakar I, Moore J, Drobniewski F, Kruijshaar M, Brown T, Yates M, Anderson C, et al.  Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. <span><span class="ref-journal">Thorax. </span>2009;<span class="ref-vol">64</span>:512–5.</span> [<a href="/pubmed/19318348" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19318348</span></a>]<div><i>(Among 678 extensively drug resistant isolates of tuberculosis reported in the UK between 2005 and 2008, 14% were also resistant to ethionamide).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury and 25 to antituberculosis agents, including 15 to isoniazid alone [ranking first], 6 to isoniazid combined with other agents, 3 to rifampin and pyrazinamide and 1 to dapsone, but none to ethionamide).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.devarbhavi.2010.2396">Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. <span><span class="ref-journal">Am J Gastroenterol. </span>2010;<span class="ref-vol">105</span>:2396–404.</span> [<a href="/pubmed/20648003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20648003</span></a>]<div><i>(Among 313 cases of drug induced liver injury seen between 1997 and 2008 at a large hospital in Bangalore, India, 181 [58%] were attributed to antituberculosis agents which accounted for 39 of 54 [72%] fatal cases; ethionamide is not specifically mentioned).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.arbex.2010.641">Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs. <span><span class="ref-journal">J Bras Pneumol. </span>2010;<span class="ref-vol">36</span>:641–56.</span> [<a href="/pubmed/21085831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21085831</span></a>]<div><i>(Analysis of adverse effects of second line drugs for tuberculosis; states that hepatotoxicity occurs in 4.3% of patients treated with ethionamide, especially in those with liver disease or alcoholism).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.caminero.2010.621">Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. <span><span class="ref-journal">Lancet Infect Dis. </span>2010;<span class="ref-vol">10</span>:621–9.</span> [<a href="/pubmed/20797644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20797644</span></a>]<div><i>(Mentions that ethionamide is a thioamide and belongs to the second line of antituberculosis medications; no discussion of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.bj_rnsson.2013.1419">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, 2 [2%] of which were attributed to antituberculosis agents, 1 isoniazid and 1 rifampin but none to ethionamide).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, 13 [7%] due to antituberculosis agents including 6 to isoniazid, 1 to pyrazinamide, 1 to rifampin and 5 to combinations).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.bhushan.2014.318">Bhushan B, Chander R, Kajal NC, Ranga V, Gupta A, Bharti H. Profile of adverse drug reactions in drug resistant tuberculosis from Punjab. <span><span class="ref-journal">Indian J Tuberc. </span>2014;<span class="ref-vol">61</span>:318–24.</span> [<a href="/pubmed/25675695" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25675695</span></a>]<div><i>(Among 207 patients from Punjab, India with tuberculosis treated with second line agents over a 2 year period, 81% developed adverse events which were severe in 35 [18%], 5 of which were hepatitis which was usually attributed to pyrazinamide; ethionamide was associated with 6 cases of hypothyroidism and 6 of acute psychosis that led to at least temporary discontinuation).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.lehloenya.2015.2648">Lehloenya RJ, Muloiwa R, Dlamini S, Gantsho N, Todd G, Dheda K. Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases. <span><span class="ref-journal">J Antimicrob Chemother. </span>2015;<span class="ref-vol">70</span>:2648–51.</span> [<a href="/pubmed/26142408" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26142408</span></a>]<div><i>(Among 69 patients [62 with HIV co-infection] who developed a severe cutaneous reaction while on combination antituberculosis therapy, 20 had recurrence when reexposed to isoniazid and 5 when reexposed to ethionamide; most had been initially exposed to both agents, but none had cross reactivity to the other, those with positive rechallenge to isoniazid being able to tolerate ethionamide and vice versa).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 54 [6%] were attributed to antituberculosis agents including 48 to isoniazid, 2 to rifampin, 2 [0.2%] to pyrazinamide, 1 to ethambutol and 1 to isoniazid and rifampin, but none to ethionamide).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.brightthomas.2016.1621">Bright-Thomas RJ, Gondker AR, Morris J, Ormerod LP. Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period. <span><span class="ref-journal">Int J Tuberc Lung Dis. </span>2016;<span class="ref-vol">20</span>:1621–4.</span> [<a href="/pubmed/27931337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27931337</span></a>]<div><i>(Among 2070 patients with tuberculosis treated over a 30 year period at a single UK referral center, 63 [3%] developed hepatitis requiring discontinuation of therapy of whom two died; the hepatitis rate was higher in whites than Asians and in females than males, and occurred more commonly with older age; 57% of cases were attributed to pyrazinamide, 32% to rifampin and 11% to</i>&#x000a0;<i>isoniazid; ethionamide not mentioned</i><i>).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.ramachandran.2015.253">Ramachandran G, Swaminathan S. Safety and tolerability profile of second-line anti-tuberculosis medications. <span><span class="ref-journal">Drug Saf. </span>2015;<span class="ref-vol">38</span>:253–69.</span> [<a href="/pubmed/25676682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25676682</span></a>]<div><i>(Review of the safety of second line drugs for tuberculosis mentions that the major adverse events with ethionamide therapy are gastrointestinal intolerance and hypothyroidism, but mentions rare events include hepatitis, rash, hypoglycemia, central nervous system effects and gynecomastia).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.thee.2016.126">Thee S, Garcia-Prats AJ, Donald PR, Hesseling AC, Schaaf HS. A review of the use of ethionamide and prothionamide in childhood tuberculosis. <span><span class="ref-journal">Tuberculosis (Edinb). </span>2016;<span class="ref-vol">97</span>:126–36.</span> [<a href="/pubmed/26586647" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26586647</span></a>]<div><i>(Review of the mechanism of action, clinical efficacy and safety of ethionamide in children with active tuberculosis mentions that adverse effects of hypothyroidism and gastrointestinal upset are common).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.xu.2017.265">Xu M, Bhatt DK, Yeung CK, Claw KG, Chaudhry AS, Gaedigk A, Pearce RE, et al.  Genetic and nongenetic factors associated with protein abundance of flavin-containing monooxygenase 3 in human liver. <span><span class="ref-journal">J Pharmacol Exp Ther. </span>2017;<span class="ref-vol">363</span>:265–74.</span> [<a href="/pmc/articles/PMC5697103/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5697103</span></a>] [<a href="/pubmed/28819071" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28819071</span></a>]<div><i>(Flavin-containing monooxygenase 3 is a human liver microsomal enzyme responsible for the activation of ethionamide and exists in variable concentrations in human livers, levels determined to some extent by genetic variation).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.dheda.2019.820">Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM. Lancet Respiratory Medicine drug-resistant tuberculosis Commission group. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <span><span class="ref-journal">Lancet Respir Med. </span>2019;<span class="ref-vol">7</span>:820–6.</span> [<a href="/pubmed/31486393" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31486393</span></a>]<div><i>(Review of the epidemiology, pathogenesis, diagnosis and management of multidrug resistant tuberculosis; does not discuss hepatotoxicity of therapeutic drug regimens).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.borisov.2019.1901522">Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, et al.  Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <span><span class="ref-journal">Eur Respir J. </span>2019;<span class="ref-vol">54</span>:1901522. </span> [<a href="/pubmed/31601711" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31601711</span></a>]<div><i>(Among 658 patients enrolled in a prospective registry of adverse events attributed to second line antituberculosis therapies, 3 serious liver related adverse events were reported including one due to ethionamide and 2 to bedaquiline).</i></div></div></li><li><div class="bk_ref" id="Ethionamide.REF.cdc">CDC. <a href="https://www.cdc.gov/tb/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.cdc.gov/tb/</a><div><i>(CDC website with up-to-date recommendations on therapy of tuberculosis).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548025</span><span class="label">PMID: <a href="/pubmed/31643357" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643357</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Ethambutol/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Ethosuximide/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548025&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548025/?report=reader">PubReader</a></li><li><a href="/books/NBK548025/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548025" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548025" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Ethionamide. [Updated 2020 Dec 26].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548025/pdf/Bookshelf_NBK548025.pdf">PDF version of this page</a> (121K)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Ethionamide/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Ethionamide: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Ethionamide" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Ethionamide: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4866854" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4866854" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4866854" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31014129" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.</a><span class="source">[Drug Dev Ind Pharm. 2019]</span><div class="brieflinkpop offscreen_noflow">Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Momin MAM, Sinha S, Tucker IG, Das SC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drug Dev Ind Pharm. 2019 Aug; 45(8):1321-1331. Epub 2019 May 21.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26844443" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[GenoType MTBDR plus 1.0® for the detection of cross-resistance between isoniazide and ethionamide in isolates of multidrug-resistant Mycobacterium tuberculosis].</a><span class="source">[Biomedica. 2015]</span><div class="brieflinkpop offscreen_noflow">[GenoType MTBDR plus 1.0® for the detection of cross-resistance between isoniazide and ethionamide in isolates of multidrug-resistant Mycobacterium tuberculosis].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Rueda J, Realpe T, Mejía G, Zapata E, Robledo J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Biomedica. 2015 Oct-Dec; 35(4):541-8. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28993337" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of &lt;i&gt;ethA&lt;/i&gt; as a Mechanism of Ethionamide Resistance.</a><span class="source">[Antimicrob Agents Chemother. 2...]</span><div class="brieflinkpop offscreen_noflow">Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of &lt;i&gt;ethA&lt;/i&gt; as a Mechanism of Ethionamide Resistance.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">de Welzen L, Eldholm V, Maharaj K, Manson AL, Earl AM, Pym AS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Antimicrob Agents Chemother. 2017 Dec; 61(12). Epub 2017 Nov 22.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23106273" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis.</a><span class="source">[Expert Rev Anti Infect Ther. 2...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wolff KA, Nguyen L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Expert Rev Anti Infect Ther. 2012 Sep; 10(9):971-81. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/6784621" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance?</a><span class="source">[Am Rev Respir Dis. 1981]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance?<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Moulding TS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am Rev Respir Dis. 1981 Mar; 123(3):262-4. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643357" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643357" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60468227ddcb804c59e37552">Ethionamide - LiverTox</a><div class="ralinkpop offscreen_noflow">Ethionamide - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:59:35-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal104&amp;ncbi_phid=CE8B33EC04669F8100000000050E0159&amp;ncbi_session=CE8B33EC04682261_1294SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548025%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548025&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548025/&amp;ncbi_pagename=Ethionamide - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B33EC04682261_1294SID /projects/books/PBooks@9.2 portal104 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>